The effects of angiotensin II (All) blockade were compared with the effects of angiotensin converting enzyme inhibition in rats with reduced nephron number. Rats were subjected to fivesixths renal ablation and divided into four groups with similar values for blood pressure and serum creatinine after 2 wk. Group 1 then served as untreated controls, while group 2 received the All receptor antagonist MK954 (which has previously been designated DuP753), group 3 received the converting enzyme inhibitor enalapril, and group 4 received a combination of reserpine, hydralazine, and hydrochlorothiazide. Micropuncture and morphologic studies were performed 10 wk later. Converting enzyme inhibition, All receptor blockade, and the combination regimen were equally effective in reversing systemic hypertension (time-averaged systolic blood pressure: group 1, 185±5 mmHg; group 2, 125±2 mmHg; group 3, 127±2 mmHg; group 4, 117±4 mmHg). Micropuncture studies showed that glomerular transcapillary pressure was reduced significantly by converting enzyme inhibition and by AII blockade but not by the combination regimen (5P: group 1, 49±1 mmHg; group 2, 42±1 mmHg; group 3, 40±2 mmHg, group 4, 47±1 mmHg). Reduction of systemic blood pressure was associated with the development of markedly less proteinuria and segmental glomerular sclerosis in rats receiving enalapril and MK954 but not in rats receiving the combination regimen (prevalence of glomerular sclerotic lesions: group 1, 41±4%; group 2, 9±1%; group 3,9±1%; group 4, 33±6%). These results indicate that the effects of converting enzyme inhibition on remnant glomerular function and structure depend on reduction in All activity and are not attributable simply to normalization of systemic blood pressure. (J. Clin. Invest. 1992. 766-771.)
Introduction
Inhibition of angiotensin converting enzyme has been shown to limit glomerular injury in several renal disease models ( [1] [2] [3] [4] [5] [6] . In rats with reduced nephron number, converting enzyme inhibition reduces both systemic and glomerular transcapillary pressure and slows the development of remnant glomerular sclerosis ( 1, 2 ) . The current study sought to establish whether these beneficial effects ofconverting enzyme inhibition are mediated by a reduction in angiotensin II (AII)' activity. Pharmacologic studies have shown that converting enzyme inhibitors not only limit production of AII but also increase levels of kinins and vasodilator prostaglandins (7) (8) (9) (10) . We therefore compared the effects of converting enzyme inhibition and All receptor blockade in rats with reduced nephron number to determine whether converting enzyme inhibitor treatment protects remnant glomeruli by reducing AII activity.
Methods
Male Munich Wistar rats weighing 270-305 g were subjected to fivesixths renal ablation as previously described ( 1, 2) . 2 wk later they were divided into four groups matched for body weight, systolic blood pressure, and serum creatinine concentration. These groups were then followed for a further period of 10 wk before micropuncture and morphologic studies. Group 1 (n = 13) received no treatment and served as controls. Group 2 (n = 10) received MK954 (Merck & Co., Inc., West Point, PA), 180 mg/liter, added to the drinking water. Group 3 (n = 9) received enalapril, 25 mg/liter, added to the drinking water. Group 4 (n = 9) received a combination of reserpine 3 mg/liter, hydralazine 40 mg/liter, and hydrochlorothiazide 13 mg/liter, added to the drinking water. Each group had free access to standard laboratory chow. Systolic blood pressure was measured weekly by the tail cuffmethod. 24-h urine protein excretion was measured once after 4 wk and twice after 9 wk of treatment.
Micropuncture studies. Rats were anesthetized with Inactin, 100 mg/kg, intraperitoneally, and placed on a temperature-regulated micropuncture table. A PE-50 tubing catheter inserted in the left femoral artery wasused for blood sampling and estimation of mean arterial pressure (AP). After tracheostomy PE-50 catheters were inserted in the internal jugular veins for infusion of saline, rat plasma obtained from retired breeder rats, and radiolabeled inulin. Saline was infused at a rate of 1.2 ml/h throughout the study. Plasma was infused in an amount equal to 1% body wt over 40 min, followed by a reduction of the infusion rate to 0.5 ml/h for the remainder of the study. After 100 min, tritiated-methoxy inulin was added to the saline to achieve an infusion rate of 40 ,Ci/h following a loading dose of - A standard mathematical model was used to derive the glomerular capillary ultrafiltration coefficient (Kf) from these values for oncotic pressure and from measured parameters ( 13) . The statistical significance ofdifferences among values for individual parameters in the four experimental groups was evaluated by the analysis of variance. Fisher's probability of least significant difference test was used to assess the significance of differences between individual group means (six comparisons) with significance defined as P < 0.05. Results are expressed as means±SE throughout.
Results
Systolic bloodpressure, serum creatinine, and body weight. Results of systolic blood pressure measurements in awake rats are depicted in Fig. 1 . The four groups were matched for blood pressure at 2 wk after renal ablation. Untreated group 1 rats exhibited sustained hypertension with systolic blood pressure averaging 185±4 mmHg over the remainder of the study period. In contrast, average systolic blood pressure over the 10-wk treatment period was reduced to 125±2 mmHg in group 2 rats, 127+2 mmHg in group Weeks after ablation Figure 1 . Systolic blood pressure (SBP) after renal ablation. Groups were matched for blood pressure at 2 wk. Untreated group 1 rats (.) exhibited sustained hypertension over the remainder of the study. Blood pressure was reduced near to normal values by All blockade in group 2 rats (tA) by converting enzyme inhibition in group 3 rats (m), and by a combination of reserpine, hydralazine, and hydrochlorothiazide in group 4 rats (o). *P < 0.05 group 2, 3, or 4 vs group 1; tP < 0.05 group 4 vs group 2; §P < 0.05 group 4 vs group 3.
4 rats. Average blood pressure values for the three treated groups were not statistically different from one another and were similar to blood pressure values observed in intact rats in our laboratory ( 14) . The four experimental groups were also matched for serum creatinine (group 1, 1.1±0.1 mg/dl; group 2, 1.2±0.1 mg/dl; group 3, 1.2±0.1 mg/dl; group 4, 1. 1±0.1 mg/dl) and for body wt (group 1, 276±3 g; group 2, 279±4 g; group 3, 269±4 g; group 4, 286±8 g) at 2 wk after ablation. Weight gain was not different among the groups over the remainder ofthe study and averaged 58±4 g in group 1, 65±4 g in group 2, 64±2 g in group 3, and 50±7 g in group 4.
Micropuncture studies. Mean values for hematocrit, arterial pressure under anesthesia (AP), whole kidney glomerular filtration rate (GFR), SNGFR, and the pressures, flows, and resistances governing glomerular ultrafiltration are summarized in Table I . Values for hematocrit were similar in the four groups. Values for AP paralleled values for systolic blood pressure in awake animals. Untreated group 1 rats exhibited marked hypertension with AP averaging 140±5 mmHg. All receptor blockade reduced AP to 98±4 mmHg in group 2 rats, converting enzyme inhibition reduced AP to 99±2 mmHg in group 3 rats, and the combination regimen reduced AP to 101±2 mmHg in group 4 rats. Systemic hypertension was associated with elevation of glomerular transcapillary hydraulic pressure (AP) in untreated group 1 rats. The value of 49±1 mmHg for zAP in these animals was similar to values observed in previous studies of rats subjected to renal ablation ( 1, 2) . In contrast, AP averaged 42 mmHg in group 2 rats and 40±2 mmHg in group 3 rats. Thus control of systemic hypertension by All receptor blockade and by converting enzyme inhibition was associated with reduction of 3P to values close to those observed in normal rats. Control of systemic hypertension by the combination regimen, however, was not associated with a similar reduction in AP. The average value for AP in group 4 rats was 47±1 mmHg. This value was significantly greater than the values for AP in groups 2 and 3 and only slightly and not significantly less than the value for 6P in group 1. Despite the lower systemic blood pressures, values for remnant kidney GFR were not reduced in the treated groups, averaging 0.91±0.07 ml/min in group 2, 0.96±0.06 ml/min in group 3, and 0.72±0.5 ml/min in group 4, as compared to a value of 0.85±0.06 ml/min in group 1. As expected, rats subjected to renal ablation exhibited prominent remnant nephron hyperfiltration with values for SNGFR increased to more than twice those observed in normal rats ( 14) . Persistant remnant nephron hyperperfusion, attributable largely to reductions in afferent arteriolar resistance, RA, contributed to the maintenance of hyperfiltration when blood pressure was reduced by drug treatment. Increased values for the ultrafiltration coefficient, Kf, also contributed to maintenance ofhyperfiltration in groups 2 and 3 treated with AII blockade and converting enzyme inhibition, but the increase in Kf attained statistical significance only in group 3. The mean value for Kf in group 4 rats receiving the combination regimen was practically identical to the mean value for Kf in group 1 rats receiving no treatment.
The effectiveness of AII receptor blockade and converting enzyme inhibition was confirmed by assessing the pressor responses to intravenous bolus infusions of angiotension I (AI) and AII at the end of the micropuncture studies. The pressor response to 50 ng of AI was 56±4 mmHg in group 1, 7±2 mmHg in group 2 (P < 0.05 vs group 1), 18±2 mmHg in group 3 (P < 0.05 vs groups 1 and 2), and 46±2 mmHg in group 4 (P < 0.05 vs groups 1, 2, and 3 ). The pressor response to 50 ng of AII was 55±6 mmHg in group 1, 8±2 mmHg in group 2 (P < 0.05 vs groups 1, 3, and 4), 54±3 mmHg in group 3, and 49±2 mmHg in group 4. Thus both MK954 and enalapril reduced the pressor response to Al but only MK954 effectively reduced the pressor response to All.
Proteinuria. Group 1 rats with systemic and glomerular hypertension developed progressive glomerular injury manifested by increasing proteinuria as depicted in Fig. 2 . Protein excretion in this group averaged 145±22 mg/d at 6 wk after ablation and 251±23 mg/d at 11 wk after ablation. All blockade and converting enzyme inhibition afforded equal protection against the development of proteinuria. Thus protein excretion in group 2 rats averaged 52±7 mm/d at 6 wk after ablation and rose only to 85±16 mg/d at 11 wk after ablation. Similarly, protein excretion in group 3 rats averaged 39±8 mg/ d at 6 wk after ablation and rose only to 67±13 mg/d at 11 wk after ablation. In contrast, reduction ofblood pressure with the combination regimen did not afford effective protection against the development of proteinuria. At Structural alterations. Results of morphologic stuc summarized in Table II . These studies disclosed that the lence of segmental glomerular lesions was closely ass with the degree of proteinuria. Group 1 rats receiving ni ment exhibited segmental lesions in 41±3% of glomern prevalence of segmental glomerular lesions was 9±1% group 2 rats receiving MK954 and in group 3 rats re enalapril, indicating that All blockade and converting e inhibition provided equivalent protection against glon structural injury. In contrast, the prevalence of segmen merular lesions was 33±6% in group 4 rats, indicatii reduction ofblood pressure with the combination regim vided significantly less, if any, protection against glor injury. As expected, values for mean glomerular volun greater than those obtained in intact rats in our lab (15). Protection against remnant glomerular injury w however, associated with a significant reduction in glor volume in rats receiving MK954 or enalapril. Average re kidney weight was slightly less in group 2 and 3 than in g Discussion Ablation of major portions of the renal mass in rats is fc by progressive sclerosis ofremnant glomeruli ( 1, 2, 16) . opment of glomerular sclerosis in this model is prece systemic and glomerular hypertension and accompar steadily increasing proteinuria. Several therapies hav shown to retard the development ofremnant glomerulai in rats subjected to renal ablation ( 16) . One of the mos tive of these therapies is inhibition of angiotensin I con enzyme. Doses ofconverting enzyme inhibitors which n ize systemic and glomerular transcapillary pressure have been shown to reduce proteinuria and largely prevent sclerosis of remnant glomeruli ( 1, 2) .
The goal of this study was to better define the pharmaco-,5 'S logic mechanism by which converting enzyme inhibitors protect remnant glomeruli. Specifically, we sought to determine whether the beneficial effects of converting enzyme inhibition are mediated by a reduction in All activity. In intact rats, infusion of All has been shown to increase glomerular transcapillary pressure and ultimately to cause progressive glomerular sclerosis (17, 18) . Reduction in All activity thus provides a * .
logical mechanism for the protective effect of converting enzyme inhibition in rats subjected to renal ablation. Converting enzyme inhibitors, however, have other pharmacologic effects which could help lower blood pressure and preserve glomerular structure following reduction of nephron number. In particular, converting enzyme inhibitors increase the activity ofkinins and may increase the activity of vasodilator prostaglandins (7) (8) (9) (10) . Recent studies suggest that increased activity of kinins contributes to the antiproteinuric effect of converting enzyme ,k after inhibition in rats with Heymann nephritis and to the antihyroteinpertensive effect of converting enzyme inhibition in rats with iition Goldblatt hypertension (9, 10). )f proTo determine whether converting enzyme inhibition prolrochlotects remnant glomeruli by reducing All activity, we compared ria at the effects of the All receptor blocker MK954 and the convert-11 wk ing enzyme inhibitor enalapril in rats subjected to renal abla-0.05 tion. MK954 is a nonpeptide All receptor blocker which is highly specific for the AT-1 receptor and can be given orally ( 19, 20) . Even in high concentrations, it has no agonist activity iies are and blocks smooth muscle contraction in response to All with- were not distinguishable from those ofconverting enzyme inhibition. Results of the current study thus strongly suggest that converting enzyme inhibition prevents glomerular injury by reducing AII activity in rats subjected to renal ablation.
Results of our study do not prove that AII activity is increased after renal ablation. It is possible that renal ablation induces a primary disturbance in some other vasomotor control system, but that the effects of this disturbance on blood pressure and glomerular structure do not develop when AII activity is reduced. Alternatively, hypertension and glomerular injury in rats subjected to renal ablation could be caused by activation ofthe renin angiotension system. Early investigators showed that circulating renin levels are not elevated in rats with reduced nephron number (24) . The hypothesis that increased renin release causes hypertension in these animals was therefore largely abandoned. It has since been recognized, however, that maintenance of "normal" values for circulating renin activity in the setting of increased blood pressure or sodium excretory load may reflect activation ofthe renin-angiotensin system (25, 26) . Thus failure of plasma renin levels to decrease despite a prominent increase in blood pressure in rats subjected to renal ablation could reflect an increase in the activity of the circulating renin angiotensin system in these animals ( 1, 24) . It is notable that Anderson et al. (27) found that plasma renin levels increased markedly when antihypertensive agents which have no direct effect on the renin angiotensin system were used to lower blood pressure in renal ablated rats. These findings suggest that enalapril and MK954 could maintain normal blood pressure following renal ablation by blocking the effect of an increase in circulating renin activity.
An additional possibility is that converting enzyme inhibition and All receptor blockade prevent an increase in the intrarenal activity of the renin-angiotensin system following renal ablation. It has recently been recognized that local activity of the renin-angiotensin system may be increased without alteration of circulating renin levels (28, 29). Within the kidney, renin is released into the perivascular interstitium, and renin concentrations in renal lymph may exceed those in plasma (30) . Angiotensinogen is also produced within the kidney, and intrarenal angiotensinogen synthesis may modulate intrarenal AII production independent of circulating renin activity (29). These observations have prompted interest in the possibility that intrarenal All activity promotes hypertension and progressive glomerular injury in renal disease (31, 32) . Proof that the activity of the intrarenal renin angiotensin system is increased in rats subjected to renal ablation has not yet been obtained. Recent studies suggest, however, that systemic and glomerular hypertension in rats subjected to renal ablation is caused by hypoperfusion of nephrons adjacent to areas of renal scarring ( 14) . Hypoperfusion ofthis nephron population could presumably stimulate release of renin into the renal interstitium and thereby cause an increase in intrarenal AII activity.
Glomerular capillary pressure was reduced along with systemic blood pressure in renal ablated rats receiving enalapril and MK954 in the current study. Glomerular transcapillary pressure remained elevated, however, when blood pressure was reduced with a combination of reserpine, hydralazine, and hydrochlorothiazide. Findings in rats treated with enalapril and with the combination regimen were similar to those originally reported by Anderson et al. (27) . The reason that these antihypertensive regimens have different effects on glomerular function remains to be elucidated. Pelayo and Westcott (33) have recently shown that acute reduction ofrenal perfusion pressure by aortic constriction reduces glomerular capillary pressure in rats subjected to renal ablation. Anderson et al. (27) showed that sustained reduction of systemic pressure by administration ofreserpine, hydralazine, and hydrochlorothiazide is associated with elevation of plasma renin levels as well as with maintenance ofglomerular hypertension in this disease model. Together, these results suggest that glomerular transcapillary pressure might initially be reduced by any therapy which reduces systemic blood pressure, but that blockade ofAII activity may be necessary for sustained reduction of glomerular transcapillary pressure along with systemic blood pressure in rats subjected to renal ablation.
Finally, it should be emphasized that the current study does not identify the mechanism by which reducing AII activity preserves remnant glomerular structure. Protection against glomerular sclerosis was associated with reduction ofglomerular transcapillary pressure both in rats receiving MK954 and in rats receiving enalapril. These findings are consistent with the hypothesis that glomerular injury in rats subjected to renal ablation is caused by capillary hypertension ( 1, 2) . The effects of AII on the glomerulus, however, are not limited to increasing transcapillary pressure. In vitro studies have shown that AII causes growth of smooth muscle and mesangial cells and may cause proliferation ofthese cells (34) (35) (36) . A sustained increase in intrarenal All activity could thus cause progressive mesangial expansion. The finding that glomerular epithelial cells have AII receptors suggests that AII could also have a direct effect on glomerular barrier function (37) . At present, it is not possible to selectively block any one of these actions of All without also blocking the others. It is thus not possible to determine whether AII receptor blockade protects remnant glomeruli by lowering glomerular transcapillary pressure or by preventing some other action of All in the remnant kidney.
